scholarly journals Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

2007 ◽  
Vol 104 (10) ◽  
pp. 4106-4111 ◽  
Author(s):  
M. G. Manfredi ◽  
J. A. Ecsedy ◽  
K. A. Meetze ◽  
S. K. Balani ◽  
O. Burenkova ◽  
...  
2010 ◽  
Vol 83 (Suppl_1) ◽  
pp. 344-344
Author(s):  
Patricia Y. Akinfenwa ◽  
Nonna V. Kolomeyevskaya ◽  
Claire M. Mach ◽  
Zhen Li ◽  
Matthew L. Anderson

2007 ◽  
Vol 27 (12) ◽  
pp. 4513-4525 ◽  
Author(s):  
Kara Hoar ◽  
Arijit Chakravarty ◽  
Claudia Rabino ◽  
Deborah Wysong ◽  
Douglas Bowman ◽  
...  

ABSTRACT Aurora A kinase plays an essential role in the proper assembly and function of the mitotic spindle, as its perturbation causes defects in centrosome separation, spindle pole organization, and chromosome congression. Moreover, Aurora A disruption leads to cell death via a mechanism that involves aneuploidy generation. However, the link between the immediate functional consequences of Aurora A inhibition and the development of aneuploidy is not clearly defined. In this study, we delineate the sequence of events that lead to aneuploidy following Aurora A inhibition using MLN8054, a selective Aurora A small-molecule inhibitor. Human tumor cells treated with MLN8054 show a high incidence of abnormal mitotic spindles, often with unseparated centrosomes. Although these spindle defects result in mitotic delays, cells ultimately divide at a frequency near that of untreated cells. We show that many of the spindles in the dividing cells are bipolar, although they lack centrosomes at one or more spindle poles. MLN8054-treated cells frequently show alignment defects during metaphase, lagging chromosomes in anaphase, and chromatin bridges during telophase. Consistent with the chromosome segregation defects, cells treated with MLN8054 develop aneuploidy over time. Taken together, these results suggest that Aurora A inhibition kills tumor cells through the development of deleterious aneuploidy.


PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e58485 ◽  
Author(s):  
Iliana A. Kesisova ◽  
Konstantinos C. Nakos ◽  
Avgi Tsolou ◽  
Dimitrios Angelis ◽  
Joe Lewis ◽  
...  

2013 ◽  
Vol 72 (6) ◽  
pp. 1255-1264 ◽  
Author(s):  
Santhosh Palani ◽  
Mayankbhai Patel ◽  
Jessica Huck ◽  
Mengkun Zhang ◽  
Suresh K. Balani ◽  
...  

2011 ◽  
Vol 17 (24) ◽  
pp. 7614-7624 ◽  
Author(s):  
Mark G. Manfredi ◽  
Jeffrey A. Ecsedy ◽  
Arijit Chakravarty ◽  
Lee Silverman ◽  
Mengkun Zhang ◽  
...  

2010 ◽  
Vol 71 (3) ◽  
pp. 675-685 ◽  
Author(s):  
Arijit Chakravarty ◽  
Vaishali Shinde ◽  
Josep Tabernero ◽  
Andres Cervantes ◽  
Roger B. Cohen ◽  
...  

2021 ◽  
Author(s):  
G. Diluvio ◽  
T. T. Kelley ◽  
M. Lahiry ◽  
A. Alvarez Trotta ◽  
E. M. Kolb ◽  
...  

Abstract Notch Activation Complex Kinase, NACK, is a component of the Notch transcriptional machinery critical to Notch-mediated tumorigenesis. However, the mechanism by which NACK regulates the Notch-mediated transcription is not well understood. Here we demonstrate that NACK binds and hydrolyses ATP and that only ATP-bound NACK is able to bind to the Notch Ternary Complex (NTC). Considering this we sought to identify inhibitors of this ATP-Dependent function and, using computational pipelines, discovered the first small molecule inhibitor of NACK, Z271-0326, that directly blocks the activity of Notch-mediated transcription and shows potent antitumor activity in PDX mouse models. In conclusion, we have discovered the first inhibitor that holds promise for efficacious treatment of Notch-driven cancers by blocking the Notch downstream NTC activity.


Sign in / Sign up

Export Citation Format

Share Document